Mephedrone in Adolescent Rats: Residual Memory Impairment and Acute but Not Lasting 5-HT Depletion

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Motbey, Craig P ^a   Karanges, Emily ^a   Li, Kong M ^b   Wilkinson, Shane ^c   Winstock, Adam R ^d   Ramsay, John ^e   Hicks, Callum ^a   Kendig, Michael D ^a   Wyatt, Naomi ^f   Callaghan, Paul D ^f   McGregor, Iain S ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b University of Sydney   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e ST GEORGE S HOSPITAL   (United Kingdom)

^f AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4' METHYLMETHCATHINONE; DOPAMINE; METHAMPHETAMINE; NEUROTRANSMITTER; SEROTONIN;

ADOLESCENT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BEHAVIOR DISORDER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DRUG EXPOSURE; HYPERACTIVITY; MALE; MEMORY DISORDER; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATTERN RECOGNITION; PROTEIN EXPRESSION; SEROTONIN BRAIN LEVEL; SEROTONIN METABOLISM; SEROTONIN RELEASE; TISSUE LEVEL;

ANIMALS; CORPUS STRIATUM; DESIGNER DRUGS; DOPAMINE; HIPPOCAMPUS; MALE; MAZE LEARNING; MEMORY DISORDERS; MEMORY, LONG-TERM; METHAMPHETAMINE; MOTOR ACTIVITY; RATS; RATS, WISTAR; SEROTONIN; WEIGHT GAIN;

RATTUS; RATTUS NORVEGICUS;

EID: 84866478711     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045473     Document Type: Article

References (63)

1. Brunt TM, Poortman A, Niesink RJ, van den Brink W (2010) Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol. doi: 10.1177/0269881110378370.
2. Dargan PI, Albert S, Wood DM, (2010) Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM 103: 875-879.
3. Newcombe R (2009) The use of mephedrone (M-cat, meow) in Middlesbrough. Manchester: Lifeline Publications.
4. Advisory Council on the Misuse of Drugs (2010) Consideration of the cathinones. London: Home Office.
5. Schifano F, Albanese A, Fergus S, Stair JL, Deluca P, et al. (2011) Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology (Berl). doi: 10.1007/s00213-010-2070-x.
6. Winstock AR, (2010) Mephedrone: its abuse liability and effect profile and the nature of legal highs. Drug Alcohol Rev 29: 82.
7. Winstock A, Mitcheson L, Ramsey J, Marsden J (2011) Mephedrone: use, subjective effects and health risks. Addiction. doi: 10.1111/j.1360-0443.2011.03502.x.
8. Motbey CP, Hunt GE, Bowen MT, Artiss S, McGregor IS, (2011) Mephedrone (4-methylmethcathinone, 'meow'): acute behavioural effects and distribution of fos expression in adolescent rats. Addict Biol 17: 409-422.
9. Kehr J, Ichinose F, Yoshitake S, Goiny M, Sievertsson T, et al. (2011) Mephedrone, compared to MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats. Br J Pharmacol. doi: 10.1111/j.1476-5381.2011.01499.x.
10. Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, et al. (2011) 4-methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther. doi: 10.1124/jpet.111.184119.
11. Martinez-Clemente J, Escubedo E, Pubill D, Camarasa J (2011) Interaction of mephedrone with dopamine and serotonin targets in rats. Eur Neuropsychopharmacol. doi: 10.1016/j.euroneuro.2011.07.009.
12. Baumann MH, Ayestas MA, Partilla JS, Sink JR, Shulgin AT, et al. (2011) The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology. doi: 10.1038/npp.2011.304.
13. Garrett G, Sweeney M (2011) The serotonin syndrome as a result of mephedrone toxicity. BMJ Case Rep. doi: 10.1136/bcr.04.2010.2925.
14. Bajaj N, Mullen D, Wylie S (2010) Dependence and psychosis with 4-methylmethcathinone (mephedrone) use. BMJ Case Rep. doi: 10.1136/bcr.02.2010.2780.
15. McGaw C, Kankam O, (2010) The co-ingestion of alcohol and mephedrone- an emerging cause of acute medical admissions in young adults and a potential cause of tachyarrhythmias. The West London medical journal 2: 9-13.
16. Wood DM, Greene SL, Dargan PI (2010) Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg Med J. doi: 10.1136/emj.2010.092288.
17. Wood DM, Davies S, Puchnarewicz M, Button J, Archer R, et al. (2010) Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. J Med Toxicol 6: 327-330.
18. Wood DM, Davies S, Greene SL, Button J, Holt DW, et al. (2010) Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol 48: 924-927.
19. Dickson AJ, Vorce SP, Levine B, Past MR, (2010) Case report: multiple-drug toxicity caused by the coadministration of 4-methylmethcathinone (mephedrone) and heroin. J Anal Toxicol 34: 162-168.
20. Gustavsson D, Escher C, (2009) [Mephedrone-Internet drug which seems to have come and stay. Fatal cases in Sweden have drawn attention to previously unknown substance]. Lakartidningen 106: 2769-2771.
21. Maskell PD, De Paoli G, Seneviratne C, Pounder DJ, (2011) Mephedrone (4-methylmethcathinone)-related deaths. J Anal Toxicol 35: 188-191.
22. Torrance H, Cooper G, (2011) The detection of mephedrone (4-methylmethcathinone) in 4 fatalities in Scotland. Forensic Sci Int 202: e62-63.
23. Angoa-Pérez M, Kane MJ, Francescutti DM, Sykes KE, Shah MM, et al. (2011) Mephedrone, an abused psychoactive component of "bath salts" and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J Neurochem. doi: 10.1111/j.1471-4159.2011.07632.x.
24. Meng H, Cao J, Kang J, Ying X, Ji J, et al. (2011) Mephedrone, a new designer drug of abuse, produces acute hemodynamic effects in the rat. Toxicol Lett 208: 62-68.
25. Clemens KJ, van Nieuwenhuyzen PS, Li KM, Cornish JL, Hunt GE, et al. (2004) MDMA ("ecstasy"), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat. Psychopharmacology 173: 318-325.
26. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI, (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55: 463-508.
27. McGregor IS, Clemens KJ, Van der Plasse G, Li KM, Hunt GE, et al. (2003) Increased anxiety 3 months after brief exposure to MDMA ('ecstasy') in rats: association with altered 5-ht transporter and receptor density. Neuropsychopharmacology 28: 1472-1484.
28. McGregor IS, Gurtman CG, Morley KC, Clemens KJ, Blokland A, et al. (2003) Increased anxiety and "depressive" symptoms months after MDMA ("ecstasy") in rats: drug-induced hyperthermia does not predict long-term outcomes. Psychopharmacology 168: 465-474.
29. Halpern JH, Sherwood AR, Hudson JI, Gruber S, Kozin D, et al. (2011) Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs. Addiction. doi: 10.1111/j.1360-0443.2010.03252.x.
30. Freeman TP, Morgan CJA, Vaughn-Jones J, Hussain N, Karimi K, et al. (2012) Cognitive and subjective effects of mephedrone and factors influencing use of a 'new legal high'. Addiction. doi: 10.1111/j.1360-0443.2011.03719.x.
31. Clemens KJ, Cornish JL, Li KM, Hunt GE, McGregor IS, (2005) MDMA ('ecstasy') and methamphetamine combined: order of administration influences hyperthermic and long-term adverse effects in female rats. Neuropharmacology 49: 195-207.
32. Clemens KJ, Cornish JL, Hunt GE, McGregor IS, (2007) Repeated weekly exposure to MDMA, methamphetamine or their combination: Long-term behavioural and neurochemical effects in rats. Drug Alcohol Depend 86: 183-190.
33. van Nieuwenhuijzen PS, Long LE, Hunt GE, Arnold JC, McGregor IS, (2010) Residual social, memory and oxytocin-related changes in rats following repeated exposure to gamma-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination. Psychopharmacology (Berl) 212: 663-674.
34. Able JA, Gudelsky GA, Vorhees CV, Williams MT, (2006) 3,4-methylenedioxymethamphetamine in adult rats produces deficits in path integration and spatial reference memory. Biol Psychiatry 59: 1219-1226.
35. Cassel JC, Riegert C, Rutz S, Koenig J, Rothmaier K, et al. (2005) Ethanol, 3,4-methylenedioxymethamphetamine (ecstasy) and their combination: long-term behavioral, neurochemical and neuropharmacological effects in the rat. Neuropsychopharmacology 30: 1870-1882.
36. Meyer JS, Piper BJ, Vancollie VE, (2008) Development and characterization of a novel animal model of intermittent MDMA ("ecstasy") exposure during adolescence. Ann N Y Acad Sci 1139: 151-163.
37. Piper BJ, Meyer JS, (2004) Memory deficit and reduced anxiety in young adult rats given repeated intermittent MDMA treatment during the periadolescent period. Pharmacol Biochem Behav 79: 723-731.
38. Mattner F, Bandin DL, Staykova M, Berghofer P, Gregoire MC, et al. (2011) Evaluation of [123I]-CLINDE as a potent SPECT radiotracer to assess the degree of astroglia activation in cuprizone-induced neuroinflammation. Eur J Nucl Med Mol Imaging 38: 1516-1528.
39. Arlicot N, Katsifis A, Garreau L, Mattner F, Vergote J, et al. (2008) Evaluation of CLINDE as potent translocator protein (18 kDa) SPECT radiotracer reflecting the degree of neuroinflammation in a rat model of microglial activation. Eur J Nucl Med Mol Imaging 35: 2203-2211.
40. Pubill D, Canudas AM, Pallàs M, Camins A, Camarasa J, et al. (2003) Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity. Naunyn Schmiedebergs Arch Pharmacol 367: 490-499.
41. Fantegrossi WE, Ciullo JR, Wakabayashi KT, De La Garza II R, Traynor JR, et al. (2008) A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse. Neuroscience 151: 533-543.
42. Syapin PJ, Alkana RL, (1988) Chronic ethanol exposure increases peripheral-type benzodiazepine receptors in brain. Eur J Pharmacol 147: 101-109.
43. Obernier JA, White AM, Swartzwelder HS, Crews FT, (2002) Cognitive deficits and CNS damage after a 4-day binge ethanol exposure in rats. Pharmacol Biochem Behav 72: 521.
44. Ball KT, Budreau D, Rebec GV, (2006) Context-dependent behavioural and neuronal sensitization in striatum to MDMA (ecstasy) administration in rats. Eur J Neurosci 24: 217-228.
45. Kalivas PW, Duffy P, White SR, (1998) MDMA elicits behavioral and neurochemical sensitization in rats. Neuropsychopharmacology 18: 469-479.
46. van Nieuwenhuijzen PS, Li KM, Hunt GE, McGregor IS, (2009) Weekly gamma-hydroxybutyrate exposure sensitizes locomotor hyperactivity to low-dose 3,4-methylenedioxymethamphetamine in rats. Neuropsychobiology 60: 195-203.
47. Klein C, Karanges E, Spiro A, Wong A, Spencer J, et al. (2011) Cannabidiol potentiates Δ 9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology (Berl) 218: 443-457.
48. Berton O, McClung CA, DiLeone RJ, Krishnan V, Renthal W, et al. (2006) Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311: 864-868.
49. Lukas M, Toth I, Reber SO, Slattery DA, Veenema AH, et al. (2011) The neuropeptide oxytocin facilitates pro-social behavior and prevents social avoidance in rats and mice. Neuropsychopharmacology 36: 2159-2168.
50. Erowid (2011) Erowid experience vaults: 4-methylmethcathinone (also mephedrone, 4-MMC, 4-MMC, meow, m-cat, 2-methylamino-1-p-tolylpropan-1-one) Main Index. Available: http://www.erowid.org/experiences/subs/exp_4Methylmethcathinone.shtml. Accessed 2012 May 22.
51. Ball KT, Klein JE, Plocinski JA, Slack R, (2011) Behavioral sensitization to 3,4-methylenedioxymethamphetamine is long-lasting and modulated by the context of drug administration. Behav Pharmacol 22: 847-850.
52. Szumlinski KK, Balogun MY, Maisonneuve IM, Glick SD, (2000) Interactions between iboga agents and methamphetamine sensitization: studies of locomotion and stereotypy in rats. Psychopharmacology 151: 234-241.
53. Wallace TL, Gudelsky GA, Vorhees CV, (2001) Neurotoxic regimen of methamphetamine produces evidence of behavioral sensitization in the rat. Synapse 39: 1-7.
54. Wiley JL, Evans RL, Grainger DB, Nicholson KL, (2008) Age-dependent differences in sensitivity and sensitization to cannabinoids and 'club drugs' in male adolescent and adult rats. Addict Biol 13: 277-286.
55. Davidson C, Lazarus C, Lee TH, Ellinwood EH, (2002) Behavioral sensitization is greater after repeated versus single chronic cocaine dosing regimens. Eur J Pharmacol 441: 75-78.
56. Drugs-Forum (2011) Experiences- Mephedrone (4-methylmethcathinone, 4-MMC) experiences. Available: http://www.drugs-forum.com/forum/showthread.php?t=43273. Accessed 2012 May 22.
57. Baumann MH, Wang X, Rothman RB, (2007) 3, 4-methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology 189: 407-424.
58. van Heeringen C, Bijttebier S, Godfrin K, (2011) Suicidal brains: A review of functional and structural brain studies in association with suicidal behaviour. Neurosci Biobehav Rev 35: 688-698.
59. Corkery JM, Schifano F, Ghodse AH (2012) Mephedrone-related fatalities in the United Kingdom: Contextual, clinical and practical issues. In: Gallelli L, editor. Pharmacology. Croatia: InTech. 355-380.
60. Osorio-Olivares M, Rezende MC, Sepulveda-Boza S, Cassels BK, Fierro A, (2004) MAO inhibition by arylisopropylamines: the effect of oxygen substituents at the beta-position. Bioorg Med Chem 12: 4055-4066.
61. Kelly JP, (2011) Cathinone derivatives: A review of their chemistry, pharmacology and toxicology. Drug Test Anal 3: 439-453.
62. Cadet JL, Krasnova IN, Jayanthi S, Lyles J, (2007) Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox Res 11: 183-202.
63. Malberg JE, Seiden LS, (1998) Small changes in ambient temperature cause large changes in 3, 4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 18: 5086-5094.